China’s biotech firms are pressing ahead with global expansion, a trend industry insiders describe as “irreversible”, even as Washington rolls out investment restrictions and national security measures aimed at slowing their advance. “The US has erected numerous regulatory and non-tariff barriers for Chinese companies seeking to enter the American market,” said Zhang Jun, co-head of the global healthcare group at Chinese investment bank Citic Securities, at the Hong Kong Exchanges and Clearing’s